86 related articles for article (PubMed ID: 10497445)
1. [Platelet aggregation test in specific immunotherapy].
Rogala B; Gumprecht J
Pneumonol Alergol Pol; 1999; 67(3-4):126-36. PubMed ID: 10497445
[TBL] [Abstract][Full Text] [Related]
2. Allergen-specific IgE in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy.
Rogala B; Glück J
J Investig Allergol Clin Immunol; 1999; 9(3):183-9. PubMed ID: 10412681
[TBL] [Abstract][Full Text] [Related]
3. Effect of allergen-specific immunotherapy on plasma level of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG), platelet activation markers in patients with house dust mite allergy.
Kasperska-Zajac A; Brzoza Z; Rogala B
Vaccine; 2007 May; 25(18):3595-8. PubMed ID: 17291641
[TBL] [Abstract][Full Text] [Related]
4. Platelet aggregation in IgE-mediated allergy with elevated soluble Fc epsilon RII/CD23 level.
Rogala B; Gumprecht J; Gawlik R; Strojek K
J Investig Allergol Clin Immunol; 1995; 5(3):161-5. PubMed ID: 7582163
[TBL] [Abstract][Full Text] [Related]
5. Effect of allergen-specific immunotherapy on platelet secretory activity in patients with grass-pollen allergy.
Kasperska-Zajac A; Brzoza Z; Rogala B
Vaccine; 2006 Nov; 24(47-48):6990-3. PubMed ID: 17011086
[TBL] [Abstract][Full Text] [Related]
6. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
7. [The effect of specific immunotherapy on serum eotaxin level in patients with pollinosis: preliminary studies].
Jahnz-Rózyk K; Głodzińska-Wyszogrodzka E; Rozyńska-Polańska R; Paluchowska E; Zabielski LS
Pol Merkur Lekarski; 2001 Sep; 11(63):244-6. PubMed ID: 11761820
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of allergic rhinitis caused by grass pollen or house-dust mites in Spain.
Valero A; Justicia JL; Antón E; Dordal T; Fernández-Parra B; Lluch M; Montoro J; Navarro AM
Am J Rhinol Allergy; 2011; 25(4):e123-8. PubMed ID: 21310119
[TBL] [Abstract][Full Text] [Related]
9. [Allergen specific-IgG4 in circulating immune complexes in patients with inhalant allergy undergoing specific immunotherapy].
Rogala B; Jarzab J; Rymarczyk B; Tłuczykont B
Wiad Lek; 2004; 57(3-4):123-30. PubMed ID: 15307518
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France.
Omnes LF; Bousquet J; Scheinmann P; Neukirch F; Jasso-Mosqueda G; Chicoye A; Champion L; Fadel R
Eur Ann Allergy Clin Immunol; 2007 May; 39(5):148-56. PubMed ID: 17626329
[TBL] [Abstract][Full Text] [Related]
11. [Platelet aggregation and receptor expression of low affinity to IgE (Fc epsilon RII CD23) in patients with seasonal allergic rhinitis].
Rogala B; Gumprecht J; Strojek K; Rogala E
Pneumonol Alergol Pol; 1993; 61(3-4):133-7. PubMed ID: 8364426
[TBL] [Abstract][Full Text] [Related]
12. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis.
Riechelmann H; Schmutzhard J; van der Werf JF; Distler A; Kleinjans HA
Am J Rhinol Allergy; 2010; 24(5):e104-9. PubMed ID: 21244725
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.
Kopp MV; Stenglein S; Kamin W; Friedrichs F; von Berg A; Zielen S; Hamelmann E; Wahn U; Kuehr J
Pediatr Allergy Immunol; 2007 Sep; 18(6):523-7. PubMed ID: 17680911
[TBL] [Abstract][Full Text] [Related]
15. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
16. Short-term efficacy of nasal immunotherapy.
Palma-Carlos AG; Santos AS; Pregal A
Allerg Immunol (Paris); 1998 Jan; 30(1):14-7. PubMed ID: 9503098
[TBL] [Abstract][Full Text] [Related]
17. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
18. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
19. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
20. [The results of specific immunotherapy for house dust mites in patients with allergic rhinitis].
Sahin E; Taş E; Dağtekin Ergür EN; Cuhali BD; Gürsel AO
Kulak Burun Bogaz Ihtis Derg; 2008; 18(2):79-84. PubMed ID: 18628641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
